Open-label study of etanercept treatment in patients with moderate-to-severe plaque psoriasis who lost a satisfactory response to adalimumab.

J BagelS TyringK C RiceD H CollierG KricorianJ ChungJ IlesB S StolshekA KaliyaperumalKim A Papp

Published in: The British journal of dermatology (2017)

Patients with psoriasis who experienced secondary failure of adalimumab achieved satisfactory response to etanercept regardless of ADA status.

Keyphrases